Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Researchers check safety of existing hemophilia drug

NCT ID NCT04682145

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

Summary

This study is collecting safety information from an existing European patient registry. It aims to monitor side effects in people with hemophilia A who are already being treated with the medication turoctocog alfa pegol. The study does not involve giving patients any new treatment or changing their care.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Novo Nordisk Investigational Site

    Søborg, 2860, Denmark

Conditions

Explore the condition pages connected to this study.